HomeInsightsStock Comparison

Cipla Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Cipla Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Last Updated on: Dec 19, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1517 as of 19 Dec 15:30.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 22.1 on March 2025 . This represents a CAGR of 0.08% over 6 yearsThe P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 16.9 on March 2025 . This represents a CAGR of -6.69% over 6 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 116434 crore on March 2025 . This represents a CAGR of 22.71% over 6 yearsThe Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 95465 crore on March 2025 . This represents a CAGR of 10.73% over 6 years.
  • The revenue of Cipla Ltd for the Sep '25 is ₹ 7858 crore as compare to the Jun '25 revenue of ₹ 7216 crore. This represent the growth of 8.9% The revenue of Dr Reddys Laboratories Ltd for the Sep '25 is ₹ 9158 crore as compare to the Jun '25 revenue of ₹ 8862 crore. This represent the growth of 3.34%.
  • The ebitda of Cipla Ltd for the Sep '25 is ₹ 2163 crore as compare to the Jun '25 ebitda of ₹ 2036 crore. This represent the growth of 6.24% The ebitda of Dr Reddys Laboratories Ltd for the Sep '25 is ₹ 2340 crore as compare to the Jun '25 ebitda of ₹ 2464 crore. This represent the decline of -5.03%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1353 crore over 10 quarters. This represents a CAGR of 13.01% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1336 crore over 10 quarters. This represents a CAGR of -1.97% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.05 % on March 2025 . This represents a CAGR of 9.87% over 6 yearsThe Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 12.47 % on March 2025 . This represents a CAGR of -2.07% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

Cipla Ltd News Hub

News

Cipla receives ESG rating of 66

Cipla announced that NSE Sustainability Ratings & Analytics, a SEBI registered ESG Rating ...

Read more

10 Dec 2025 15:02

News

Cipla Ltd spurts 0.37%, gains for fifth straight session

Cipla Ltd is up for a fifth straight session today. The stock is quoting at Rs 1524.9, up ...

Read more

13 Nov 2025 13:00

News

Cipla slides 5% in two days after management rejig, Q2 results

The stock has fallen 4.55% in two trading sessions since the announcement. The drug major ...

Read more

31 Oct 2025 12:25

News

Cipla partners with Eli Lilly to distribute Tirzepatide in India under second brand 'Yurpeak'

'The introduction of a second brand of Tirzepatide in India through our commercial agreeme...

Read more

24 Oct 2025 13:09

News

Cipla to announce Quarterly Result

Cipla will hold a meeting of the Board of Directors of the Company on 30 October 2025. Pow...

Read more

25 Sep 2025 09:50

News

Cipla Ltd spurts 2.93%, gains for third straight session

Cipla Ltd is up for a third straight session in a row. The stock is quoting at Rs 1566.2, ...

Read more

13 Aug 2025 13:05

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys Laboratories allots 9,165 equity shares under ESOS

Dr Reddys Laboratories has allotted 9,165 equity shares under ESOS on 09 December 2025. Po...

Read more

09 Dec 2025 17:27

News

Dr Reddy's Lab arm inks pact with Immutep SAS for novel cancer immunotherapy

Eftilagimod alfa is a novel immunotherapy with the potential to set a new standard of care...

Read more

08 Dec 2025 15:24

News

Dr Reddys Laboratories Ltd up for five straight sessions

Dr Reddys Laboratories Ltd rose for a fifth straight session today. The stock is quoting a...

Read more

01 Dec 2025 13:00

News

Dr Reddys Lab gains after securing EC nod for AVT03

AVT03 is a human monoclonal IgG2 antibody and biosimilar candidate to Prolia and Xgeva, wh...

Read more

25 Nov 2025 09:50

News

Dr. Reddy's receives EC marketing authorization for AVT03 (denosumab)

Dr Reddys Laboratories announced that the European Commission (EC) has granted marketing a...

Read more

24 Nov 2025 17:34

News

Dr Reddys Laboratories Ltd up for fifth session

Dr Reddys Laboratories Ltd is up for a fifth straight session in a row. The stock is quoti...

Read more

17 Nov 2025 13:00

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Dr Reddys Laboratories Ltd

Which company has a larger market capitalization, Cipla Ltd or Dr Reddys Laboratories Ltd?

Market cap of Cipla Ltd is 122,538 Cr while Market cap of Dr Reddys Laboratories Ltd is 106,740 Cr

What are the key factors driving the stock performance of Cipla Ltd and Dr Reddys Laboratories Ltd?

The stock performance of Cipla Ltd and Dr Reddys Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Dr Reddys Laboratories Ltd?

As of December 19, 2025, the Cipla Ltd stock price is INR ₹1517.0. On the other hand, Dr Reddys Laboratories Ltd stock price is INR ₹1278.9.

How do dividend payouts of Cipla Ltd and Dr Reddys Laboratories Ltd compare?

To compare the dividend payouts of Cipla Ltd and Dr Reddys Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions